Physicians

Department / Division
Medicine / Medicine - Gastroenterology

Address
DUMC 3913
Durham, NC 27710

Appointment Telephone
919-684-6437

Office Telephone
919-684-3262

Fax Telephone
919-684-8857

Training

• MD, University of Missouri-Kansas City School of Medicine, 1992

Residency

• Internal Medicine, Mayo Clinic (Minnesota), 1992-1995

Fellowship

• Gastroenterology/Hepatology, Mayo Clinic (Arizona and Minnesota), 1995-1998

Other Training

• MPH, University of Florida, 2004

Clinical Interests
Obesity-related liver disease and the metabolic syndrome of insulin resistance, including evaluation of new treatment options and the impact of fatty liver from a public health perspective

Research Interests
My research interests include metabolic liver disease, particularly obesity-related liver disease and its association with complications of the insulin resistance syndrome.  I am interested in studying the clinical, environmental, and genetic risk factors for nonalcoholic fatty liver disease, new therapeutic options for treatment, and evaluating the impact of NAFLD from a public health perspective.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Genentech, Inc (Roche Holding)
• Takeda Pharmaceutical Co. Ltd.

Representative Publications
Abdelmalek MF, Diehl AM. De Novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl. 2007 Jun;13(6):788-90. (2007) Abstract

Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am J Gastroenterol. 2007 Jun;102(6):1333-4. (2007) Abstract

Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR. Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006 Sep;4(9):1162-9. (2006) Abstract

Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, Cabrera R, Reed AI, Liu C, Nelson DR. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 2006 Jan;12(1):51-7. (2006) Abstract

Machicao VI, Srinivas TR, Hemming AW, Soldevila-Pico C, Firpi RJ, Reed AI, Morelli GJ, Nelson DR, Abdelmalek MF. Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation. Liver Transpl. 2006 May;12(5):754-61. (2006) Abstract

Lucey MR, Abdelmalek MF, Gagliardi R, Granger D, Holt C, Kam I, Klintmalm G, Langnas A, Shetty K, Tzakis A, Woodle ES. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant. 2005 May;5(5):1111-9. (2005) Abstract

Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2004 Feb;10(2):199-207. (2004) Abstract

Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, Reed AI, Hemming AW, Liu C, Crawford JM, Nelson DR. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 2004 Oct;10(10):1240-7. (2004) Abstract

Abdelmalek MF, Pasha TM, Zein NN, Persing DH, Wiesner RH, Douglas DD. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl. 2003 Dec;9(12):1253-7. (2003) Abstract

Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, Van Der Werf W, Lauwers G, Liu C, Crawford JM, Davis GL, Nelson DR. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl. 2002 Nov;8(11):1000-6. (2002) Abstract

Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001 Sep;96(9):2711-7. (2001) Abstract

Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, Howard R, Davis GL. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2001 Dec;7(12):1064-70. (2001) Abstract

Abdelmalek MF, Harrison ME, Gross JB Jr, Poterucha JJ, Gossard AA, Spivey JR, Rakela J, Lindor KD. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial. J Clin Gastroenterol. 1998 Mar;26(2):130-4. (1998) Abstract